Chandra S, Brummelhuis H G
Vox Sang. 1981 Nov-Dec;41(5-6):257-73. doi: 10.1111/j.1423-0410.1981.tb01048.x.
Prothrombin complex concentrates prepared for clinical use are reviewed with emphasis on frequently observed adverse reactions such as viral hepatitis and thromboembolic complications. Preparation procedures and quality control are described briefly, and the use of these concentrates in the treatment of hemophilia A patients who develop factor VIII inhibitors is also described. The causes of and methods for the detection of potential thrombogenicity are discussed and suggestions which may result in a safer product are made.
对用于临床的凝血酶原复合物浓缩剂进行了综述，重点关注常见的不良反应，如病毒性肝炎和血栓栓塞并发症。简要描述了制备程序和质量控制，并介绍了这些浓缩剂在治疗产生Ⅷ因子抑制剂的甲型血友病患者中的应用。讨论了潜在血栓形成性的原因和检测方法，并提出了可能产生更安全产品的建议。
